| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1018155989 |
| P356 | DOI | 10.1038/SJ.ONC.1205362 |
| P698 | PubMed publication ID | 11948395 |
| P5875 | ResearchGate publication ID | 11419024 |
| P50 | author | Klas Wiman | Q57419790 |
| Vladimir J N Bykov | Q88401820 | ||
| Galina Selivanova | Q50923870 | ||
| P2093 | author name string | Alan R Fersht | |
| Stefan M V Freund | |||
| Thomas M Rippin | |||
| P2860 | cites work | Pharmacological rescue of mutant p53 conformation and function | Q73316566 |
| Thermodynamic stability of wild-type and mutant p53 core domain | Q24648879 | ||
| Solution structure of the tetrameric minimum transforming domain of p53 | Q27730258 | ||
| Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations | Q27730815 | ||
| The crystal structure of cyclic ADP-ribose | Q28296221 | ||
| p53 mutations in human cancers | Q28302973 | ||
| p53: puzzle and paradigm | Q29618407 | ||
| Rescuing the function of mutant p53. | Q30329984 | ||
| p53-induced apoptosis as a safeguard against cancer. | Q33766705 | ||
| Hot-spot mutants of p53 core domain evince characteristic local structural changes. | Q35549859 | ||
| Semirational design of active tumor suppressor p53 DNA binding domain with enhanced stability | Q36753352 | ||
| Functional dissection of p53 tumor suppressor protein | Q38349795 | ||
| The single-stranded DNA end binding site of p53 coincides with the C-terminal regulatory region. | Q38353041 | ||
| Mechanism of rescue of common p53 cancer mutations by second-site suppressor mutations | Q40386946 | ||
| Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy | Q40774297 | ||
| P433 | issue | 14 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 2119-2129 | |
| P577 | publication date | 2002-03-01 | |
| P1433 | published in | Oncogene | Q1568657 |
| P1476 | title | Characterization of the p53-rescue drug CP-31398 in vitro and in living cells | |
| P478 | volume | 21 |
| Q35640128 | A new therapeutic basis for treating Li-Fraumeni Syndrome breast tumors expressing mutated TP53. |
| Q40023794 | A novel p53 rescue compound induces p53-dependent growth arrest and sensitises glioma cells to Apo2L/TRAIL-induced apoptosis |
| Q38934098 | Aggregation and Prion-Like Properties of Misfolded Tumor Suppressors: Is Cancer a Prion Disease? |
| Q35397889 | Apoptosis in cancer: from pathogenesis to treatment |
| Q35014385 | Awakening guardian angels: drugging the p53 pathway |
| Q38845711 | CP-31398 inhibits the growth of p53-mutated liver cancer cells in vitro and in vivo |
| Q38911627 | CP-31398 prevents the growth of p53-mutated colorectal cancer cells in vitro and in vivo |
| Q36173604 | CP-31398 restores mutant p53 tumor suppressor function and inhibits UVB-induced skin carcinogenesis in mice |
| Q40616862 | CP-31398, a novel p53-stabilizing agent, induces p53-dependent and p53-independent glioma cell death |
| Q24800091 | CP-31398, a putative p53-stabilizing molecule tested in mammalian cells and in yeast for its effects on p53 transcriptional activity |
| Q33642043 | Characterization and optimization of a novel protein-protein interaction biosensor high-content screening assay to identify disruptors of the interactions between p53 and hDM2. |
| Q34409021 | Complementation of two mutant p53: implications for loss of heterozygosity in cancer |
| Q33989650 | Determination and stability of CP-31398 in plasma from experimental animals by LC-MS/MS. |
| Q35101871 | Drug discovery and p53. |
| Q43043487 | Folding and misfolding mechanisms of the p53 DNA binding domain at physiological temperature |
| Q36032244 | Genotoxicity of the cancer chemopreventive drug candidates CP-31398, SHetA2, and phospho-ibuprofen |
| Q30985752 | Implementation of a 220,000-compound HCS campaign to identify disruptors of the interaction between p53 and hDM2 and characterization of the confirmed hits |
| Q40362071 | Mutant p53 melanoma cell lines respond differently to CP-31398-induced apoptosis |
| Q41968106 | Mutant p53 targeting by the low molecular weight compound STIMA-1 |
| Q36070574 | Mutant p53: one name, many proteins |
| Q35597613 | Novel cancer therapy by reactivation of the p53 apoptosis pathway. |
| Q50562075 | Optimal allosteric stabilization sites using contact stabilization analysis. |
| Q37191174 | Pharmacological activation of p53 in cancer cells |
| Q30389604 | Pharmacological reactivation of mutant p53: from protein structure to the cancer patient |
| Q50014672 | Pharmacoperones as Novel Therapeutics for Diverse Protein Conformational Diseases |
| Q26801512 | Protein Folding and Mechanisms of Proteostasis |
| Q36777373 | Reactivation of mutant p53: molecular mechanisms and therapeutic potential |
| Q39529355 | Reactivation of p53 mutants by prima-1 [corrected] in thyroid cancer cells. |
| Q35099531 | Recent advances in p53 research and cancer treatment |
| Q37088668 | Rescue of mutants of the tumor suppressor p53 in cancer cells by a designed peptide |
| Q36710840 | Restoration of wild-type p53 function in human cancer: relevance for tumor therapy. |
| Q30831001 | Restoration of wild-type p53 function in human tumors: strategies for efficient cancer therapy. |
| Q37818291 | Restoring p53 tumor suppressor activity as an anticancer therapeutic strategy |
| Q39205536 | Reviving the guardian of the genome: Small molecule activators of p53. |
| Q27027835 | Small molecule compounds targeting the p53 pathway: are we finally making progress? |
| Q27677872 | Small molecule induced reactivation of mutant p53 in cancer cells |
| Q35204556 | Small molecules that reactivate mutant p53. |
| Q34740058 | Stabilization of p53 by CP-31398 inhibits ubiquitination without altering phosphorylation at serine 15 or 20 or MDM2 binding. |
| Q36430162 | Strategies for therapeutic targeting of the p53 pathway in cancer. |
| Q36786022 | Structural biology of the tumor suppressor p53 and cancer-associated mutants |
| Q27651295 | Targeted rescue of a destabilized mutant of p53 by an in silico screened drug |
| Q26770856 | Targeting Oncogenic Mutant p53 for Cancer Therapy |
| Q37564349 | Targeting cancer stem cells with p53 modulators. |
| Q47291772 | Targeting mutant p53 for efficient cancer therapy. |
| Q36173619 | Targeting mutant p53 shows promise for sunscreens and skin cancer |
| Q33655329 | Targeting p53 for Novel Anticancer Therapy |
| Q91643844 | Targeting the Oncogenic p53 Mutants in Colorectal Cancer and Other Solid Tumors |
| Q37260683 | Targeting the p53 pathway |
| Q34069279 | Targeting wild-type and mutant p53 with small molecule CP-31398 blocks the growth of rhabdomyosarcoma by inducing reactive oxygen species-dependent apoptosis. |
| Q91816686 | The Diverse Functions of Mutant 53, Its Family Members and Isoforms in Cancer |
| Q38340912 | The Wilms tumor suppressor-1 target gene podocalyxin is transcriptionally repressed by p53. |
| Q49571721 | The curcumin analog HO-3867 selectively kills cancer cells by converting mutant p53 protein to transcriptionally active wildtype p53. |
| Q27690770 | The p53 pathway as a target in cancer therapeutics: obstacles and promise |
| Q90196924 | The pharmalogical reactivation of p53 function improves breast tumor cell lysis by granzyme B and NK cells through induction of autophagy |
| Q35567279 | The role of p53 in chemosensitivity and radiosensitivity. |
| Q36430748 | The role of p53 mutations as a prognostic factor and therapeutic target in inflammatory breast cancer |
| Q37081504 | The use of p53 as a tool for human cancer therapy |
| Q39474871 | Therapeutic reactivation of mutant p53 protein by quinazoline derivatives |
| Q38042630 | Therapeutic strategies for head and neck cancer based on p53 status |
| Q35783751 | Towards an understanding of the role of p53 in adrenocortical carcinogenesis |
| Q35708113 | Translational approaches targeting the p53 pathway for anti-cancer therapy |
| Q24796110 | Treatment of terminal peritoneal carcinomatosis by a transducible p53-activating peptide |
| Q34324683 | Tumor protein p53 (TP53) testing and Li-Fraumeni syndrome : current status of clinical applications and future directions |
| Q58760242 | Virtual screening using covalent docking to find activators for G245S mutant p53 |
| Q57929625 | p53 latency – out of the blind alley |
| Q37750115 | p53-based cancer therapy |
Search more.